,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1195,1,2,,48416135,27661,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
1,2517,2,1,,144205134,27661,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
2,76635,8,1,,103408641,27661,Unspecified,,,,,Compound was evaluated for the effective dose in guinea pig heart using Langendorff assay,Other,,
3,167448,3,4,,103408641,27661,Unspecified,,,,,Compound was evaluated for reduction of arterial medium pressure of rabbit by 30 mm Hg,Other,,
4,188056,2,4,,103408641,27661,Unspecified,,,,,Compound was evaluated for T-wave increase of rat EKG measured as percent reduction after 30 min at a dosage of 60 mg/kg,Other,,
5,188057,2,4,,103408641,27661,Unspecified,,,,,Compound was evaluated for T-wave increase of rat EKG measured as percent reduction after 30 min at a dosage of 8 mg/kg,Other,,
6,409946,3,9,,103408641,27661,Inactive,113980.0,4129.0,,,Inhibition of human recombinant MAOB at 100 uM by fluorimetric method,Other,18834112.0,
7,409951,3,9,,103408641,27661,Inactive,113980.0,4129.0,,,Inhibition of human liver MAOB,Other,18834112.0,
8,424015,6,3,,103408641,27661,Active,,,9.6,EC50,"Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in absence of guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one",Confirmatory,19361986.0,
9,424016,6,3,,103408641,27661,Unspecified,,,100.0,EC50,"Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in presence of 10 uM guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one",Confirmatory,19361986.0,
10,425652,7,2,,103408641,27661,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
11,425653,7,2,,103408641,27661,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
12,444050,7,1,,103408641,27661,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
13,444051,6,2,,103408641,27661,Unspecified,,,,,Total clearance in human,Other,20070106.0,
14,444052,6,2,,103408641,27661,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
15,444053,6,2,,103408641,27661,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
16,444054,6,1,,103408641,27661,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
17,444055,3,3,,103408641,27661,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
18,444056,3,3,,103408641,27661,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
19,444057,3,3,,103408641,27661,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
20,444058,6,2,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
21,445826,3,9,,103408641,27661,Inactive,115449.0,759.0,,,Inhibition of human carbonic anhydrase 1 up to 100 uM by CO2 hydrase stopped flow assay,Other,19854054.0,
22,445827,3,9,,103408641,27661,Inactive,115456.0,760.0,,,Inhibition of human carbonic anhydrase 2 up to 100 uM by CO2 hydrase stopped flow assay,Other,19854054.0,
23,445828,3,9,,103408641,27661,Inactive,115465.0,762.0,,,Inhibition of human carbonic anhydrase 4 up to 100 uM by CO2 hydrase stopped flow assay,Other,19854054.0,
24,445829,3,4,,103408641,27661,Unspecified,,,,,Reduction of intraocular pressure in normotensive New Zealand white rabbit at 55 mM,Other,19854054.0,
25,445830,5,3,,103408641,27661,Unspecified,,,,,Reduction of intraocular pressure in normotensive New Zealand white rabbit assessed as time to reach maximal difference at 55 mM,Other,19854054.0,
26,445831,6,2,,103408641,27661,Unspecified,,,,,Solubility at pH 6,Other,19854054.0,
27,445832,5,3,,103408641,27661,Active,,,10.8,EC50,Vasorelaxant activity against methoxiamin-induced contraction in rabbit aortic ring,Confirmatory,19854054.0,
28,540209,4,3,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
29,540210,4,3,,103408641,27661,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
30,540211,2,5,,103408641,27661,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
31,540212,4,3,,103408641,27661,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
32,540213,4,3,,103408641,27661,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
33,540214,4,3,,103408641,27661,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
34,540215,3,2,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
35,540216,4,3,,103408641,27661,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
36,540217,4,3,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
37,540218,4,3,,103408641,27661,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
38,540219,4,3,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
39,540220,4,3,,103408641,27661,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
40,540221,4,3,,103408641,27661,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
41,588211,2,3,,103408641,27661,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
42,588212,2,3,,103408641,27661,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
43,588213,2,3,,103408641,27661,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
44,588214,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
45,588215,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
46,588216,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
47,588217,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
48,588218,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
49,588219,2,3,,103408641,27661,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
50,588220,2,3,,103408641,27661,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
51,588834,2,1,,144205134,27661,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
52,598018,1,3,,103408641,27661,Unspecified,,,,,Antiglaucoma activity in New Zealand rabbits assessed as inhibition of carbomer-induced ocular hypertension at 2 % in 50 uL administered into eye after 2 to 3 weeks of carbomer challenge (Rvb = 35.3 +/- 1.2 mmHg),Other,21549597.0,
53,598020,1,3,,103408641,27661,Unspecified,,,,,Inhibition of carbomer-induced ocular hypertension in New Zealand rabbits assessed as time for maximal IOP lowering efficacy at 2 % in 50 uL administered into eye after 2 to 3 weeks of carbomer challenge,Other,21549597.0,
54,624349,1,2,,92308037,27661,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
55,625279,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
56,625280,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
57,625281,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
58,625282,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
59,625283,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
60,625284,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
61,625285,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
62,625286,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
63,625287,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
64,625288,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
65,625289,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
66,625290,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
67,625291,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
68,625292,1,3,,103408641,27661,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
69,651631,4,1,,144205134,27661,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
70,651632,4,1,,144205134,27661,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
71,651633,4,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
72,651634,4,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
73,652048,1,2,,144205134,27661,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
74,652051,1,1,,144205134,27661,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
75,686978,1,1,,144205134,27661,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
76,686979,1,1,,144205134,27661,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
77,720516,2,1,,144205134,27661,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
78,720532,1,1,,144205134,27661,Inconclusive,420597.0,,10.0,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
79,720533,1,1,,144205134,27661,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
80,720552,2,1,,144205134,27661,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
81,720634,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
82,720635,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
83,720637,2,1,,144205134,27661,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
84,720641,1,2,,92308037,27661,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
85,720674,2,2,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
86,720675,2,2,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
87,720678,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
88,720679,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
89,720680,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
90,720681,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
91,720682,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
92,720683,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
93,720684,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
94,720685,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
95,720686,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
96,720687,2,2,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
97,720691,4,1,,144205134,27661,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
98,720692,3,1,,144205134,27661,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
99,720693,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
100,720717,1,3,,92308037,27661,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
101,720719,2,1,,144205134,27661,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
102,720725,2,1,,144205134,27661,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
103,743012,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
104,743014,3,1,,144205134,27661,Inconclusive,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
105,743015,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
106,743033,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
107,743035,2,1,,144205134,27661,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
108,743036,2,1,,144205134,27661,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
109,743040,3,1,,144205134,27661,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
110,743041,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
111,743042,3,1,,144205134,27661,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
112,743053,2,1,,144205134,27661,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
113,743054,2,1,,144205134,27661,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
114,743063,2,1,,144205134,27661,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
115,743064,3,1,,144205134,27661,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
116,743065,3,1,,144205134,27661,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
117,743066,3,1,,144205134,27661,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
118,743067,2,1,,144205134,27661,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
119,743069,2,1,,144205134,27661,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
120,743074,2,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
121,743075,2,1,,144205134,27661,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
122,743077,2,1,,144205134,27661,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
123,743078,2,1,,144205134,27661,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
124,743079,3,1,,144205134,27661,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
125,743080,3,1,,144205134,27661,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
126,743081,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
127,743083,3,1,,144205134,27661,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
128,743084,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
129,743085,3,1,,144205134,27661,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
130,743086,3,1,,144205134,27661,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
131,743091,2,1,,144205134,27661,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
132,743094,3,1,,144205134,27661,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
133,743122,2,1,,144205134,27661,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
134,743139,2,1,,144205134,27661,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
135,743140,2,1,,144205134,27661,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
136,743244,1,1,,144205134,27661,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
137,745127,3,1,,103408641,27661,Unspecified,,,,,Chemical stability of the compound in phosphate buffer assessed as nitrite release after 4 hrs at pH 7.4 by Griess method,Other,23541836.0,
138,745128,1,1,,103408641,27661,Unspecified,,,,,Vasorelaxant activity against acetylcholine-induced contraction in rat aortic rings at 100 uM,Other,23541836.0,
139,747766,3,1,,103408641,27661,Unspecified,,,,,Induction of nitrite release in phosphate buffer at pH 7.4 at 10'-4 M after 4 hrs by Griess method,Other,23639542.0,
140,747768,1,1,,103408641,27661,Inconclusive,,,,,Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BChE,Other,23639542.0,
141,747769,2,3,,103408641,27661,Inconclusive,21362409.0,100033901.0,,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate after 5 mins by Ellman's method,Confirmatory,23639542.0,
142,747770,2,3,,103408641,27661,Inconclusive,14916521.0,,,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 5 mins by Ellman's method,Confirmatory,23639542.0,
143,1159580,2,1,,268734976,27661,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
144,1159620,1,1,,103408641,27661,Active,,,,,Summary of drug indications.,Other,,
145,1224863,1,1,,316919159,27661,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
146,1259310,1,1,,321949391,27661,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
147,1259310,1,1,,333494056,27661,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
148,1259344,1,1,,144205134,27661,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
149,1259355,1,1,,144205134,27661,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
150,1259356,1,1,,144205134,27661,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
151,1259407,1,1,,363899861,27661,Inactive,,,,,CCRIS mutagenicity studies,Other,,
152,1259416,1,2,,340081169,27661,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
153,1259421,1,1,,177748777,27661,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
154,1259421,1,1,,340081169,27661,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
